Cargando…

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting

BACKGROUND: Successful delivery and completion of tuberculosis preventive treatment are necessary for tuberculosis elimination. Shorter preventive treatment regimens currently have higher medication costs, but patients spend less time in care and are more likely to complete treatment. It is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuen, Courtney M, Majidulla, Arman, Jaswal, Maria, Safdar, Nauman, Malik, Amyn A, Khan, Aamir J, Becerra, Mercedes C, Keshavjee, Salmaan, Lu, Chunling, Hussain, Hamidah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423476/ https://www.ncbi.nlm.nih.gov/pubmed/33289039 http://dx.doi.org/10.1093/cid/ciaa1835

Ejemplares similares

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting
por: Pease, Christopher, et al.
Publicado: (2021)

Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
Publicado: (2021)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
por: Sharan, Riti, et al.
Publicado: (2022)

Sources of Multidrug Resistance in Patients With Previous Isoniazid-Resistant Tuberculosis Identified Using Whole Genome Sequencing: A Longitudinal Cohort Study
por: Srinivasan, Vijay, et al.
Publicado: (2020)

Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus
por: Theron, Gerhard, et al.
Publicado: (2020)

Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection
por: Huang, Hung-Ling, et al.
Publicado: (2020)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data
por: Kalk, Emma, et al.
Publicado: (2020)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Evaluation of the Accuracy of 99DOTS, a Novel Cellphone-based Strategy for Monitoring Adherence to Tuberculosis Medications: Comparison of DigitalAdherence Data With Urine Isoniazid Testing
por: Thomas, Beena E, et al.
Publicado: (2020)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail
por: Juarez-Reyes, Maria, et al.
Publicado: (2016)

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study
por: Lam, Chee Kin, et al.
Publicado: (2018)

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis
por: Yu, Ya-Yen, et al.
Publicado: (2019)

Isoniazid and alopecia
por: Wiwanitkit, Somsri, et al.
Publicado: (2011)

Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study
por: Heyd, Amber, et al.
Publicado: (2021)

Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis — Colorado, 2011–2012
por: Bargman, Carolyn, et al.
Publicado: (2013)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
por: Nwana, Nwabunie, et al.
Publicado: (2019)

High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study
por: Yang, Heng, et al.
Publicado: (2021)

Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection
por: Wang, Tsai-Yu, et al.
Publicado: (2022)

Isoniazid-induced alopecia
por: Gupta, K. B., et al.
Publicado: (2011)

Alopecia caused by isoniazid
por: Dixit, Ramakant, et al.
Publicado: (2014)

Isoniazid and Pulmonary Fibrosis
por: Chung, Chae Uk, et al.
Publicado: (2015)

Isoniazid metabolism and hepatotoxicity
por: Wang, Pengcheng, et al.
Publicado: (2016)

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
por: Alvarez, G. G., et al.
Publicado: (2020)

Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis
por: Kendall, Emily A., et al.
Publicado: (2021)

Ringing the alarm bell: Time to scale up drug-resistant tuberculosis preventive treatment
por: Malik, Amyn A., et al.
Publicado: (2021)

Isoniazid causing pleural effusion
por: Singh, S.K., et al.
Publicado: (2008)

Isoniazid- and ethambutol-induced psychosis
por: R., Prasad, et al.
Publicado: (2008)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

Isoniazid-induced Immune Thrombocytopenia
por: Kuwabara, Gaku, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4nfm57bdntbmouamafao0gb4b4